The company’s existing North American manufacturing capacity was limited and unable to meet the market demand, resulting in long lead times for both catalog made to stock (MTS) and custom made to order (MTO)/ engineered to order (ETO) media and buffers products.
The company had experienced market share loss in key market segments and required additional manufacturing capacity to optimize their ability to serve the US market.
GeminiBio offered the company a compelling value proposition based on GeminiBio’s diversity of cGMP process liquid manufacturing capabilities, including 500-liter, 1,000-liter, 5,000-liter, and 10,000-liter single use and stainless-steel mixing vessels.
GeminiBio collaborated with the company to complete an extensive audit process and define the end-to-end business processes to cover both made-to-stock (MTS) catalog products and made-to-order (MTO)/ engineered to order (ETO) end-customer custom media and buffers.
GeminiBio worked with the customer to complete required validations and stability studies as part of the MTS product portfolio. In addition, all products manufactured to the company’s specifications included GeminiBio’s use of the company’s proprietary single use containment, filters, manifolds, packaging, and other proprietary components.
As part of the contract manufacturing agreement, GeminiBio committed to market-leading service level agreements (SLAs) to ensure the company was able to provide an industry leading customer experience to their end customers.
By leveraging GeminiBio’s scalable liquid manufacturing capabilities (10-liters to 10,000-liters), rapid feasibility, and custom product design process, as well as 10-week manufacturing lead times, the company was able to significantly improve their ability to serve the North American market, as well as offer an improved customer experience compared to their competitors.